GLTO · NASDAQ · Medical - Pharmaceuticals

Galecto (GLTO)

Preclinical biotech targeting mutant calreticulin blood disorders.

$21.58
At close−0.75 (−3.36%)

Something off on this page? Send us feedback.

EPSReportedEstimate

Aug '24Nov '24Mar '25May '25Aug '25Nov '25Mar '26May '26
Reported−$4.00−$3.39−$5.22−$1.92−$2.60−$2.36−$3.24−$0.62
Estimate−$8.00−$3.70−$3.12−$0.14−$0.39
Surprise+50.0%+8.4%−67.3%−2,216.4%−59.9%

RevenueReportedEstimate

Aug '24Nov '24Mar '25May '25Aug '25Nov '25Mar '26May '26
Reported
Estimate
Surprise

History

DateEstimateReportedSurprise
Aug 2026−$0.45
May 2026−$0.39−$0.62−59.9%
Mar 2026−$0.14−$3.24−2,216.4%
Nov 2025−$2.36
Aug 2025−$2.60

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
May 2025
Mar 2025
Nov 2024
Aug 2024
Apr 2024
Mar 2024
Nov 2023
Jul 2023
Apr 2023
Mar 2023
Nov 2022
Jul 2022
Apr 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Oct 2020
Sep 2020
Jun 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Aug 5, 2026−$0.45
May 12, 2026−$0.39−$0.62−59.9%+4.6%
Mar 18, 2026−$0.14−$3.24−2,216.4%−9.2%
Nov 6, 2025−$2.36−15.0%
Aug 5, 2025−$2.600.0%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
May 8, 2025
Mar 19, 2025
Nov 1, 2024
Aug 12, 2024
Apr 29, 2024
Mar 8, 2024
Nov 6, 2023
Jul 31, 2023
Apr 28, 2023
Mar 9, 2023
Nov 8, 2022
Jul 29, 2022
Apr 29, 2022
Feb 17, 2022
Nov 4, 2021
Aug 5, 2021
May 4, 2021
Mar 29, 2021
Oct 30, 2020
Sep 2, 2020
Jun 30, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Jun 30, 2018
Mar 31, 2018